SubsidieMeestersClinical validation of a novel non-opioid analgesic derived from the Portuguese sea for treating chronic pain
Sea4Us aims to clinically validate its novel analgesic Sea4Pain for chronic pain treatment, facilitating rapid market entry and sustainable growth through licensing and reinvestment.
Projectdetails
Introduction
Sea4Us is a world-class biotechnology company with a focus on translating marine-derived compounds with therapeutic potential for unmet medical needs into pharmaceutical assets. Sea4Us has developed a platform focused on drug discovery and the development of novel pharmaceuticals based on its core expertise in ion channels and marine biology. Sea4Us is particularly focused on developing and commercializing therapies for chronic pain.
Chronic Pain and Its Impact
Sea4Us has developed a ground-breaking therapeutic drug to treat chronic pain in patients. Chronic pain affects 100 million people across Europe and 1.6 billion globally, having a devastating impact on quality of life.
Prevalence and Burden
- Pain is the most common reason people visit their doctors.
- It is a leading cause of disability.
- Chronic pain presents an enormous social and economic burden, costing Europe alone over 500 billion Euros a year.
Current Treatment Limitations
There are many medications on the market for treating chronic pain, but they are either ineffective for most types of chronic pain and/or have adverse side effects. Opioid drugs are the most effective treatment but also inflict drug addiction, habituation, and other noxious side effects.
Sea4Pain: A Novel Solution
Our novel analgesic molecule, Sea4Pain, has a unique mechanism of action, meaning it is highly effective at treating chronic pain without any known side effects, unlike current drugs on the market. Sea4Pain is a first-in-class drug and has the potential to ease the suffering of billions of people globally.
Project Overview: Sea4Market
This EIC Accelerator project, called Sea4Market, will enable us to clinically validate our novel analgesic through the completion of First-in-Human trials and out-license our technology to make a rapid entry into the multi-billion Euro Chronic Pain market.
Importance of EIC Support
EIC support is essential to deliver this high-risk, high-reward project and will enable the sustainable growth of our business. We will reinvest revenues from our licensing deal back into our project pipeline to address other unmet medical needs and ensure the sustainable growth of our company.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.035 |
| Totale projectbegroting | € 3.570.051 |
Tijdlijn
| Startdatum | 1-3-2024 |
| Einddatum | 28-2-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- SEA4US - BIOTECNOLOGIA E RECURSOS MARINHOS, S.A.penvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Development of a Complete Triple Action Injectable Treatment for OsteoarthritisRelevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients. | EIC Transition | € 2.398.115 | 2022 | Details |
Chronic PAIN eradiCAtion by taRgeting Schwann cEllsPAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization. | ERC POC | € 150.000 | 2023 | Details |
Oral oxytocin for abdominal painThis project aims to develop gut-stable peptide analgesics for effective oral treatment of chronic abdominal pain, addressing a significant unmet medical need and reducing socio-economic burdens. | ERC POC | € 150.000 | 2023 | Details |
SEAFORHet project ontwikkelt een innovatieve SEAFOR-technologie met real-time sensoren en AI om voedselveiligheid van zeevruchten te verbeteren en verspilling met 30% te verminderen. | MIT Haalbaarheid | € 19.980 | 2022 | Details |
Development of a Complete Triple Action Injectable Treatment for Osteoarthritis
Relevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients.
Chronic PAIN eradiCAtion by taRgeting Schwann cElls
PAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization.
Oral oxytocin for abdominal pain
This project aims to develop gut-stable peptide analgesics for effective oral treatment of chronic abdominal pain, addressing a significant unmet medical need and reducing socio-economic burdens.
SEAFOR
Het project ontwikkelt een innovatieve SEAFOR-technologie met real-time sensoren en AI om voedselveiligheid van zeevruchten te verbeteren en verspilling met 30% te verminderen.